Focus on Diabetes Care

Back to articles

New Company, New Drugs: Amylin Products Add to Diabetes Arsenal

KEY POINT

Upstart biotechnology companies are known for their ability to identify and develop innovative products that add importantly to the range of choices available to patients and clinicians. Amylin Pharmaceuticals, a San Diego–based company, repeated that magic this spring, bringing its first two products to market, an amylin analog, pramlintide (Symlin), and an incretin mimetic, exenatide (Byetta; comarketed with Lilly).

SOURCES

Uwaifo GI, Ratner RE. Novel pharmacologic agents for type 2 diabetes. Endocrinol Metab Clin North Am. 2005;34:155–97.

Kendall DM et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083–91.

DeFronzo RA et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092–100.

Buse JB et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628–35.